Document Detail

Cefodizime in clinical use: a review of the clinical trial reports.
MedLine Citation:
PMID:  2074246     Owner:  NLM     Status:  MEDLINE    
The clinical efficacy of cefodizime has been tested in several open and comparative studies, above all in lower respiratory tract infections (LRTI) and uncomplicated urinary tract infections (UTI), performed in 151 centres in Europe, Latin America, South-Eastern Asia and South Africa. Of 3791 patients, 2260 could be evaluated for efficacy and safety. Comparative studies in LRTI were carried out vs cefotaxime and cefuroxime (301 vs 299 patients); both clinical and bacteriological results were superimposable (range of satisfactory clinical outcomes from 86% to 95%; bacteriological eradication 95% to 100%). In open studies (533 evaluable patients) the percentage of clinical successes ranged from 79.1% to 91.8% and the bacteriological eradication from about 87% to 90%, according to the type of infections. Comparative studies (cefodizime vs cefuroxime or ceftizoxime) in UTI again demonstrated the equivalence of treatment. In open studies (374 evaluable patients) the percentage of satisfactory clinical outcomes ranged from 84.6% in complicated upper UTI to 95.9% in lower uncomplicated UTI, with overall bacteriological eradication of 92.7%. Side effects could be evaluated in 5801 patients (Western and Japanese clinical studies); 3.79% of patients showed side effects (1.99% gastrointestinal disturbances, 0.9% rash or urticaria, 0.9% other effects); 1.13% of patients required discontinuation of treatment. No relevant changes in laboratory parameters were observed. Cefodizime has been shown to be an effective and safe agent in the treatment of LRTI and UTI caused by susceptible pathogens. A dosage regimen of 1 g every 12 h seems to be the most suitable schedule for the treatment of LRTI while 1 g every 12 h or 2 g every 24 h can equally well be adopted for treatment of UTI.
G G Grassi
Related Documents :
15619496 - Linezolid eradicates mrsa better than vancomycin from surgical-site infections.
3300316 - Use of norfloxacin in the treatment of acute diarrheal disease.
16451406 - Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
3182456 - A clinical comparative study of ofloxacin and pivampicillin in acute exacerbations of c...
8886696 - Sequential addition of low dose of medrogestone or medroxyprogesterone acetate to trans...
317036 - The effect of low frequency magnetic fields on the healing of the osteotomized rabbit r...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Review    
Journal Detail:
Title:  The Journal of antimicrobial chemotherapy     Volume:  26 Suppl C     ISSN:  0305-7453     ISO Abbreviation:  J. Antimicrob. Chemother.     Publication Date:  1990 Nov 
Date Detail:
Created Date:  1991-04-15     Completed Date:  1991-04-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7513617     Medline TA:  J Antimicrob Chemother     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  117-25     Citation Subset:  IM    
University of Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bacterial Infections / drug therapy*
Cefotaxime / analogs & derivatives*,  therapeutic use
Clinical Trials as Topic
Reg. No./Substance:
63527-52-6/Cefotaxime; 69739-16-8/cefodizime

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy and tolerance of cefodizime in the treatment of acute pyelonephritis.
Next Document:  Clinical safety profile of cefodizime.